BURLINGAME, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Electro-Signaling (NPES™), announced today it will host an investor conference call on September 7, 2016, at 4:30 p.m. EDT / 1:30 p.m. PDT. The company will highlight progress to date and provide an overview of corporate strategies, financials, and future milestones.
"In this first investor call since our public offering, we look forward to sharing ongoing progress and highlighting key milestones through 2016 and early 2017," stated Darrin Uecker, president and CEO of Pulse Biosciences. “We are investing in the expansion of our internal team and continued development of PulseTx™, our clinical system featuring the world’s first tunable NPES treatment platform. Further, we are working with key opinion leaders in key markets to identify therapeutic targets and initiate pilot studies with PulseTx™. We join in their enthusiasm about the potential and value of our unique treatment approach across several significant markets, including immuno-oncology, dermatology and veterinary medicine, as well as for the very large market for tissue treatment applications.”
Conference Call Details
Pulse Biosciences’ Darrin Uecker, president and CEO, and other senior executives will host the investor conference call on September 7, 2016, at 4:30 p.m. EDT / 1:30 p.m. PDT. For both "listen-only" participants and those who wish to take part in the question and answer portion of the call, the telephone dial-in number is (844) 494-0190 (U.S. toll-free) or (508) 637-5580 (international) with Conference ID 61405063. A link to the webcast will be made available on the Investor Section of the company's website at www.pulsebiosciences.com following the call.
About Pulse Biosciences
Pulse Biosciences (Nasdaq:PLSE) is a medical technology company developing a therapeutic tissue treatment platform based on Nano-Pulse Electro-Signaling (NPES™), a proprietary bioelectronics technology. Published pre-clinical studies have shown that a single, brief exposure of target tissue to NPES initiates a cascade of events within cells and in the surrounding microenvironment that results in apoptosis (cell death) and the priming of a durable adaptive immune response. Pulse Biosciences is pursuing a variety of applications for NPES that exploit its inherent advantages in lesion control and healing, including immuno-oncology, dermatology, aesthetics, and veterinary medicine. Clinical studies are being planned for the first commercial NPES system designed to support a broad array of electrodes for use in superficial, minimally-invasive, and open surgical procedures. More information is available at www.pulsebiosciences.com.
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, the development of Pulse Biosciences’ business, statements relating to future uses and markets for its NPES technology, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pulse Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pulse Biosciences’ most recent filings with the Securities and Exchange Commission, including Pulse Biosciences’ most recent reports on Forms S-1, as amended, and 10-Q, and include those listed under the caption “Risk Factors.”
Pulse Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
